Skip to content
2000
Volume 16, Issue 1
  • ISSN: 1871-5206
  • E-ISSN: 1875-5992

Abstract

Chemotherapy may still be an essential component to treat cancer in combination with new targeted therapies. But chemotherapy needs to get smarter in order to make those combination regimens more effective and also more tolerable, particularly for an aging population. We describe the first time the synthesis and pharmacological testing of a fusion molecule comprising of the alkylator bendamustine and the HDAC-inhibitor vorinostat. The drug was designed to allow for the exploitation of both mechanisms of action simultaneously with the goal to provide a molecule with superior efficacy over the single agents. The pharmacological testing confirms the full functional capacity of both moieties and encouraging pharmacological data raises the hope that the drug may turn out to be a great addition to the armentarium of anticancer agents.

Loading

Article metrics loading...

/content/journals/acamc/10.2174/1871520615666150518092027
2016-01-01
2025-05-12
Loading full text...

Full text loading...

/content/journals/acamc/10.2174/1871520615666150518092027
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test